{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-210428","form_type":"8-K","ticker":"SLN","cik":"0001479615","company_name":"Silence Therapeutics plc","filed_at":"2026-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.343897+00:00","generated_at":"2026-05-14T21:35:43.730559+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Silence Therapeutics Q1 net loss $15M; Phase 2 PV trial on track for August 2026 topline","bullets":["Net loss of $15.0M ($0.11 per share) vs $28.5M ($0.20) a year ago; revenue from AstraZeneca collaboration $0.4M.","Cash, cash equivalents & short-term investments at $70.1M as of March 31, 2026.","R&D expenses fell to $9.1M from $20.8M, primarily due to zerlasiran Phase 3 readiness completed in 2025.","Phase 2 SANRECO trial of divesiran for polycythemia vera ongoing; topline results expected August 2026.","Phase 1 abstracts for divesiran (EHA) and SLN312/AZD1705 (EAS) accepted for upcoming congress presentations."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-210428","json":"https://secwatch.observer/filing/0001193125-26-210428.json","markdown":"https://secwatch.observer/filing/0001193125-26-210428.md","text":"https://secwatch.observer/filing/0001193125-26-210428.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479615/000119312526210428/0001193125-26-210428-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479615/000119312526210428/sln-20260507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T21:35:43.730559+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b72c2d50ab8cc026011baad4bd52ca7f32d2fa11","claim":"Silence Therapeutics plc reported the first quarter ended March 31, 2026 results: revenue $0.4 million, net income Net loss was $15.0 million, or $0.11 basic and diluted net loss per share, EPS $0.11 basic and diluted net loss per share.","evidence_excerpt":"cash equivalents of $5.7 million and short-term investments of $64.4 million. • Collaboration Revenue: Collaboration revenue recognized under our agreement with AstraZeneca was $0.4 million for the three months ended March 31, 2026, compared to $0.1 million for the three months ended March 31, 2025. • R&D Expenses: Research and development (R&D) expenses were $9.1","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1479615/000119312526210428/0001193125-26-210428-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001104659-26-058204","ticker":"EXPI","company_name":"eXp World Holdings, Inc.","filed_at":"2026-05-11T23:59:59+00:00","headline":"eXp World Holdings Q1 revenue $1.0B (+5% YoY), net loss narrows to $(5.1M), Adj. EBITDA $4.1M (+88%)","event_type":"earnings","sec_items":["2.02","7.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-058204","json":"https://secwatch.observer/filing/0001104659-26-058204.json","markdown":"https://secwatch.observer/filing/0001104659-26-058204.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1495932/000110465926058204/0001104659-26-058204-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1495932/000110465926058204/agnt-20260511x8k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"cash equivalents of $5.7 million and short-term investments of $64.4 million. • Collaboration Revenue: Collaboration revenue recognized under our agreement with AstraZeneca was $0.4 million for the three months ended March 31, 2026, compared to $0.1 million for the three months ended March 31, 2025. • R&D Expenses: Research and development (R&D) expenses were $9.1","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1479615/000119312526210428/0001193125-26-210428-index.htm","comparable_excerpt":"the company's scale and our focus on operational efficiency across eXp World Holdings,” said Jesse Hill, Chief Financial Officer of eXp World Holdings. “We generated revenue of $1.0 billion and Adjusted EBITDA of $4.1 million, an 88% improvement that further strengthened our financial position. More recently, we executed the strategic NextHome acquisition using cash","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1495932/000110465926058204/0001104659-26-058204-index.htm"}},{"accession":"0001193125-26-215679","ticker":"HAIN","company_name":"HAIN CELESTIAL GROUP INC","filed_at":"2026-05-11T23:59:59+00:00","headline":"Hain Celestial reports Q3 FY2026 earnings; detailed figures not included in filing excerpt","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-215679","json":"https://secwatch.observer/filing/0001193125-26-215679.json","markdown":"https://secwatch.observer/filing/0001193125-26-215679.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/910406/000119312526215679/0001193125-26-215679-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/910406/000119312526215679/hain-20260511.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"cash equivalents of $5.7 million and short-term investments of $64.4 million. • Collaboration Revenue: Collaboration revenue recognized under our agreement with AstraZeneca was $0.4 million for the three months ended March 31, 2026, compared to $0.1 million for the three months ended March 31, 2025. • R&D Expenses: Research and development (R&D) expenses were $9.1","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1479615/000119312526210428/0001193125-26-210428-index.htm","comparable_excerpt":"On May 11, 2026, The Hain Celestial Group, Inc. (the “Company”) issued a press release announcing financial results for its third quarter ended March 31, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/910406/000119312526215679/0001193125-26-215679-index.htm"}},{"accession":"0001193125-26-215752","ticker":"HRTX","company_name":"HERON THERAPEUTICS, INC. /DE/","filed_at":"2026-05-11T23:59:59+00:00","headline":"Heron Q1 net revenue $34.7M (-10.8% YoY); Acute Care up 32%; guidance reaffirmed","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-215752","json":"https://secwatch.observer/filing/0001193125-26-215752.json","markdown":"https://secwatch.observer/filing/0001193125-26-215752.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/818033/000119312526215752/0001193125-26-215752-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818033/000119312526215752/hrtx-20260511.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"cash equivalents of $5.7 million and short-term investments of $64.4 million. • Collaboration Revenue: Collaboration revenue recognized under our agreement with AstraZeneca was $0.4 million for the three months ended March 31, 2026, compared to $0.1 million for the three months ended March 31, 2025. • R&D Expenses: Research and development (R&D) expenses were $9.1","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1479615/000119312526210428/0001193125-26-210428-index.htm","comparable_excerpt":"Reaffirms Guidance - Q1 2026 net revenue growth year-over year for Acute Care franchise (+32%), including ZYNRELEF ® (+27%) and APONVIE ® (+50%) - Q1 2026 total net revenue of $34.7 million - Reached settlement with Baxter Healthcare Corporation in CINVANTI ® patent litigation - Reaffirmed 2026 full-year guidance of $173–$183 million net revenue; $10–$20 million","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/818033/000119312526215752/0001193125-26-215752-index.htm"}},{"accession":"0001274737-26-000027","ticker":"XGN","company_name":"EXAGEN INC.","filed_at":"2026-05-11T23:59:59+00:00","headline":"Exagen Q1 2026: Record revenue $17.3M, net loss $4.0M; FY guidance reaffirmed","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001274737-26-000027","json":"https://secwatch.observer/filing/0001274737-26-000027.json","markdown":"https://secwatch.observer/filing/0001274737-26-000027.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1274737/000127473726000027/0001274737-26-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1274737/000127473726000027/exdx-20260511.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"cash equivalents of $5.7 million and short-term investments of $64.4 million. • Collaboration Revenue: Collaboration revenue recognized under our agreement with AstraZeneca was $0.4 million for the three months ended March 31, 2026, compared to $0.1 million for the three months ended March 31, 2025. • R&D Expenses: Research and development (R&D) expenses were $9.1","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1479615/000119312526210428/0001193125-26-210428-index.htm","comparable_excerpt":"Trailing-twelve-month average selling price (ASP) $ 444 $ 419 Cash and cash equivalents $ 21,513 $ 11,194 First Quarter 2026 Highlights: • Achieved record total revenue of $17.3 million, an increase of 12% compared to first quarter 2025. • Grew AVISE CTD test volume 10% compared to first quarter 2025. • Expanded AVISE CTD trailing-twelve-month ASP to $444 per","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1274737/000127473726000027/0001274737-26-000027-index.htm"}},{"accession":"0001544206-26-000032","ticker":"CGBD","company_name":"Carlyle Secured Lending, Inc.","filed_at":"2026-05-11T23:59:59+00:00","headline":"Carlyle Secured Lending Q1 NII $0.36/sh; NAV down 2.3% to $15.89; declares $0.35 dividend","event_type":"earnings","sec_items":["2.02","7.01","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001544206-26-000032","json":"https://secwatch.observer/filing/0001544206-26-000032.json","markdown":"https://secwatch.observer/filing/0001544206-26-000032.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1544206/000154420626000032/0001544206-26-000032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1544206/000154420626000032/csl-20260511.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"cash equivalents of $5.7 million and short-term investments of $64.4 million. • Collaboration Revenue: Collaboration revenue recognized under our agreement with AstraZeneca was $0.4 million for the three months ended March 31, 2026, compared to $0.1 million for the three months ended March 31, 2025. • R&D Expenses: Research and development (R&D) expenses were $9.1","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1479615/000119312526210428/0001193125-26-210428-index.htm","comparable_excerpt":"For the first quarter of 2026, we reported $0.36 per common share of Net Investment Income and Adjusted Net Investment Income, a non-GAAP financial measure described below.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1544206/000154420626000032/0001544206-26-000032-index.htm"}},{"accession":"0001628280-26-033124","ticker":"OPAL","company_name":"OPAL Fuels Inc.","filed_at":"2026-05-11T23:59:59+00:00","headline":"OPAL Fuels Q1 2026 Adj EBITDA $16.7M, net loss $(5.6)M; revenue down 14% YoY","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-033124","json":"https://secwatch.observer/filing/0001628280-26-033124.json","markdown":"https://secwatch.observer/filing/0001628280-26-033124.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842279/000162828026033124/0001628280-26-033124-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842279/000162828026033124/opal-20260511.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"cash equivalents of $5.7 million and short-term investments of $64.4 million. • Collaboration Revenue: Collaboration revenue recognized under our agreement with AstraZeneca was $0.4 million for the three months ended March 31, 2026, compared to $0.1 million for the three months ended March 31, 2025. • R&D Expenses: Research and development (R&D) expenses were $9.1","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1479615/000119312526210428/0001193125-26-210428-index.htm","comparable_excerpt":"Revenue for the three months ended March 31, 2026 and 2025, was $73.4 million and $85.4 million respectively, a decrease of (14)%, compared to the same period last year. 1 • Net (loss) income for the three months ended March 31, 2026 was $(5.6) million, compared to $1.3 million in the same period last year. • Basic and diluted net loss per share attributable to Class A common shareholders for the three months ended months ended March 31, 2026 were $(0.09) compared to $(0.01) in the comparable period last year.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1842279/000162828026033124/0001628280-26-033124-index.htm"}},{"accession":"0001868726-26-000035","ticker":"OLPX","company_name":"OLAPLEX HOLDINGS, INC.","filed_at":"2026-05-11T23:59:59+00:00","headline":"Olaplex Q1 net sales up 2.5% to $99.4M but swings to net loss of $5.3M; adjusted EBITDA falls 26.1%","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001868726-26-000035","json":"https://secwatch.observer/filing/0001868726-26-000035.json","markdown":"https://secwatch.observer/filing/0001868726-26-000035.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1868726/000186872626000035/0001868726-26-000035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1868726/000186872626000035/olpx-20260511.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"cash equivalents of $5.7 million and short-term investments of $64.4 million. • Collaboration Revenue: Collaboration revenue recognized under our agreement with AstraZeneca was $0.4 million for the three months ended March 31, 2026, compared to $0.1 million for the three months ended March 31, 2025. • R&D Expenses: Research and development (R&D) expenses were $9.1","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1479615/000119312526210428/0001193125-26-210428-index.htm","comparable_excerpt":"team for their continued dedication and commitment to our transformation.\" For the first quarter of 2026 compared to the first quarter of 2025: • Net sal es increased 2.5% to $99.4 million; ◦ By channel: ▪ Specialty Retail decreased 13.3% to $33.4 million; ▪ Professional increased 12.3% to $38.8 million; ▪ Direct-To-Consumer increased 13.8% to $27.2 million; ◦ Net","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1868726/000186872626000035/0001868726-26-000035-index.htm"}},{"accession":"0001140361-26-020059","ticker":"FEMY","company_name":"FEMASYS INC","filed_at":"2026-05-08T23:59:59+00:00","headline":"Femasys reports Q1 net income of $846K; sales up 24.5%; cash sufficient into Q3 2026","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-020059","json":"https://secwatch.observer/filing/0001140361-26-020059.json","markdown":"https://secwatch.observer/filing/0001140361-26-020059.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339005/000114036126020059/0001140361-26-020059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339005/000114036126020059/ef20072749_8k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"cash equivalents of $5.7 million and short-term investments of $64.4 million. • Collaboration Revenue: Collaboration revenue recognized under our agreement with AstraZeneca was $0.4 million for the three months ended March 31, 2026, compared to $0.1 million for the three months ended March 31, 2025. • R&D Expenses: Research and development (R&D) expenses were $9.1","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1479615/000119312526210428/0001193125-26-210428-index.htm","comparable_excerpt":"addressing critical unmet needs with safe, technologically advanced products.” Financial Results for Quarter Ended March 31, 2026 • Sales increased by $83,625, or 24.5%, to $424,889 in 2026\n from $341,264 in 2025, primarily due to sales of FemBloc. • Research and development expenses decreased by $1,659,071, or 55.9%, to $1,309,401 in 2026 compared to","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1339005/000114036126020059/0001140361-26-020059-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}